Oxcia AB (publ) (“Oxcia”) has today published its Annual Report for 2024.
The Annual Report is available in Swedish at: https://oxcia.com/investor/finansiella-rapporter/.
In the report, CEO Ulrika Warpman Berglund comments:
"Oxcia has a platform that provides us with many opportunities. Our focus is now on OXC-101 in AML and OXC-201 in IPF, where we believe we have the potential to demonstrate strong results."
The Annual General Meeting will be held on 23 June 2025 at 13:00 at Fogdevreten 2, Solna.
For more information contact:
Ulrika Warpman Berglund, CEO, Oxcia AB (publ)
Telephone: +46 (0) 73 270 9605
ulrika.warpmanberglund@oxcia.com
Briefly about Oxcia AB
Oxcia’s aim is to improve and extend lives by developing new innovative treatments based on our unique technology platform, O2-DDR. Oxcia AB is a pioneer in oxidative DNA damage and DNA Damage Response (DDR – the processes the body uses to repair the damage that occurs to DNA) with a focus on developing new safe and effective treatments for patients suffering from diseases caused by cancer or inflammation. Oxcia currently has two O2-DDR lead drug candidates, both with the potential to become first-in-class drugs. OXC-101 is in early clinical development as novel cancer therapy. OXC-201 is developed against idiopathic pulmonary fibrosis, and is in the preclinical phase. The portfolio also includes exploratory projects, e.g in psoriasis.
More information about Oxcia is available at www.oxcia.com